Publications | Flatiron Health | Comparative effectiveness

Browse every publication tagged Comparative effectiveness

October 2026
Real-world comparative effectiveness of trifluridine-tipiracil + bevacizumab vs trifluridine-tipiracil in patients with refractory metastatic colorectal cancer in the United States
May 2026
Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancer
- Comparative effectiveness
- Lung cancer
May 2026
Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab
May 2026
Machine learning risk stratification in a US-based database to identify subgroups of patients with head and neck cancer who benefit from adding chemotherapy to pembrolizumab
December 2025
Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)
December 2025
Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy
October 2025
Treatment duration and subsequent treatments of first-line CDK4/6i plus aromatase inhibitor for HR+/HER2- metastatic breast cancer in US routine clinical practice
- Comparative effectiveness
- Breast cancer
September 2025
Key considerations for assessing real-world comparative effectiveness in the context of the Drug Price Negotiation program: A case study of pembrolizumab
- Comparative effectiveness
- Lung cancer
September 2025
Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice
- Comparative effectiveness
- Breast cancer